Orexo ABShs Aktie
| 2,41EUR | -0,04EUR | -1,64% | 
WKN: A0HG6G / ISIN: SE0000736415
Personal
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 138 | 121 | 126 | 116 | 110 | 
| Umsatz pro Mitarbeiter in Mio. EUR | 4,81 | 4,67 | 4,95 | 5,51 | 5,36 | 
Bilanz (in Mio. SEK) - Aktiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 832 | 866 | 736 | 459 | 446 | 
| Summe Anlagevermögen | 401 | 408 | 374 | 328 | 148 | 
| Summe Aktiva | 1 233 | 1 274 | 1 109 | 787 | 595 | 
Bilanz (in Mio. SEK) - Passiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 674 | 924 | 915 | 728 | 721 | 
| Summe Eigenkapital | 559 | 350 | 194 | 59 | -126 | 
| Summe Passiva | 1 233 | 1 274 | 1 109 | 787 | 595 | 
Adresse
| Virdings allé 32 A, 754 50 Uppsala | |
| Telefon | +46 (18) 780-88-00 | 
| Internet | http://www.orexo.se | 
Management
| 
						Cecilia Coupland
						 Vice President & Head-Operations  | 
				
| 
						Christine Rankin
						 Independent Director  | 
				
| 
						Edward Kim
						 Chief Medical Officer  | 
				
| 
						Fredrik Järrsten
						 Chief Financial Officer & Executive Vice President  | 
				
| 
						Friedrich von Bohlen und Halbach
						 Chairman  | 
				
| 
						George Frederick Wilkinson
						 Independent Director  | 
				
| 
						Jonas Savmarker
						 Scientific Director  | 
				
| 
						Lena Wange
						 Manager-Communications & Investor Relations  | 
				
| 
						Nikolaj Sørensen
						 President & Chief Executive Officer  | 
				
| 
						Robert Rönn
						 SVP & Head-Research & Development  | 
				
| 
						Robin Evers
						 Independent Director  | 
				
| 
						Staffan Lindstrand
						 Independent Director  |